Page last updated: 2024-09-04

rupatadine and Carcinoma, Ovarian Epithelial

rupatadine has been researched along with Carcinoma, Ovarian Epithelial in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Beyer, S; Burges, A; Chelariu-Raicu, A; Czogalla, B; Deuster, E; Hester, A; Hysenaj, I; Jeschke, U; Kahaly, M; Kolben, T; Kraus, F; Mahner, S; Mayr, D; Schmoeckel, E; Trillsch, F	1

Other Studies

1 other study(ies) available for rupatadine and Carcinoma, Ovarian Epithelial

Article	Year
The Platelet-Activating Factor Receptor's Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine. Cells, 2021, 09-07, Volume: 10, Issue:9 Topics: Aged; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cyproheptadine; ErbB Receptors; Female; Humans; Middle Aged; Ovarian Neoplasms; Ovary; Platelet Activating Factor; Platelet Membrane Glycoproteins; Prognosis; Receptors, G-Protein-Coupled; Signal Transduction; Treatment Outcome	2021

Article

Year

The Platelet-Activating Factor Receptor's Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine.

Cells, 2021, 09-07, Volume: 10, Issue:9

Topics: Aged; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cyproheptadine; ErbB Receptors; Female; Humans; Middle Aged; Ovarian Neoplasms; Ovary; Platelet Activating Factor; Platelet Membrane Glycoproteins; Prognosis; Receptors, G-Protein-Coupled; Signal Transduction; Treatment Outcome

2021